287 related articles for article (PubMed ID: 15168719)
1. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
Gulick R
AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
[TBL] [Abstract][Full Text] [Related]
2. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
Fisher M
AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718
[TBL] [Abstract][Full Text] [Related]
4. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
5. New antiretrovirals and new combinations.
Havlir DV; Lange JM
AIDS; 1998; 12 Suppl A():S165-74. PubMed ID: 9632999
[TBL] [Abstract][Full Text] [Related]
6. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
7. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
8. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy.
Sommadossi JP
AIDS; 1998; 12 Suppl 3():S1-8. PubMed ID: 15168717
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA;
HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011
[TBL] [Abstract][Full Text] [Related]
10. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
11. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
[TBL] [Abstract][Full Text] [Related]
12. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
13. ddI and d4T plus protease inhibitors.
GMHC Treat Issues; 1996 Nov; 10(11):8-9. PubMed ID: 11364012
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.
Côté HC; Yip B; Asselin JJ; Chan JW; Hogg RS; Harrigan PR; O'Shaughnessy MV; Montaner JS
J Infect Dis; 2003 Jun; 187(12):1972-6. PubMed ID: 12792876
[TBL] [Abstract][Full Text] [Related]
15. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Winston A; McAllister J; Amin J; Cooper DA; Carr A
HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
[TBL] [Abstract][Full Text] [Related]
16. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon ED; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P;
J Acquir Immune Defic Syndr; 2004 Jun; 36(2):693-701. PubMed ID: 15167288
[TBL] [Abstract][Full Text] [Related]
17. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells.
Carter MM; Torres SM; Cook DL; McCash CL; Yu M; Walker VE; Walker DM
Environ Mol Mutagen; 2007; 48(3-4):239-47. PubMed ID: 17358029
[TBL] [Abstract][Full Text] [Related]
18. [Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T].
Mouroux M; Izopet J; Descamps D; Delaugerre C; Yvon-Groussin A; Angleraud F; Coutellier A; Bonmarchand M; Valantin MA; Matheron S; Agut H; Katlama C; Brun-Vezinet F; Calvez V
Pathol Biol (Paris); 2000 Jun; 48(5):508-12. PubMed ID: 10949850
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of mutations that confer resistance to nucleoside analogs and protease inhibitors in HIV-1-infected patients. Study Group on Resistance to Antiretroviral Agents].
Martínez G; Sarría L; Campelo C; Merchán A; Cisterna R
Rev Esp Quimioter; 1999 Dec; 12(4):317-24. PubMed ID: 10855010
[TBL] [Abstract][Full Text] [Related]
20. Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Launay O; Gérard L; Morand-Joubert L; Flandre P; Guiramand-Hugon S; Joly V; Peytavin G; Certain A; Lévy C; Rivet S; Jacomet C; Aboulker JP; Yéni P;
Clin Infect Dis; 2002 Nov; 35(9):1096-105. PubMed ID: 12384844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]